Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ad5CMV-p53 gene |
Trade Name | |
Synonyms | Advexin|INGN-201|RPR/INGN-201|Adeno-p53|Ad-p53 |
Drug Descriptions |
Advexin (Ad5CMV-p53) is a replication-defective adenoviral-CMV vector that encodes a wild-type Tp53 gene, which induces tumor cells to produce wild-type Tp53 to block cell cycle progression (PMID: 19169960). |
DrugClasses | p53 Gene Therapy 4 |
CAS Registry Number | 600735-73-7 |
NCIT ID | C2471 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ad5CMV-p53 gene | Ad5CMV-p53 gene | 1 | 0 |
Ad5CMV-p53 gene + Capecitabine | Ad5CMV-p53 gene Capecitabine | 0 | 1 |
Ad5CMV-p53 gene + Nivolumab | Ad5CMV-p53 gene Nivolumab | 0 | 2 |
Ad5CMV-p53 gene + Pembrolizumab | Ad5CMV-p53 gene Pembrolizumab | 0 | 1 |
Ad5CMV-p53 gene + unspecified PD-1 antibody | Ad5CMV-p53 gene unspecified PD-1 antibody | 0 | 0 |